"Aromatase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that inhibit AROMATASE in order to reduce production of estrogenic steroid hormones.
| Descriptor ID |
D047072
|
| MeSH Number(s) |
D27.505.519.389.870.300 D27.505.696.399.450.327.149 D27.505.696.399.450.855.300
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Aromatase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Aromatase Inhibitors".
This graph shows the total number of publications written about "Aromatase Inhibitors" by people in this website by year, and whether "Aromatase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 1 | 0 | 1 |
| 2010 | 2 | 0 | 2 |
| 2012 | 1 | 1 | 2 |
| 2014 | 2 | 1 | 3 |
| 2015 | 2 | 0 | 2 |
| 2016 | 1 | 3 | 4 |
| 2017 | 2 | 0 | 2 |
| 2019 | 1 | 0 | 1 |
| 2020 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Aromatase Inhibitors" by people in Profiles.
-
Endocrine therapy initiation among women diagnosed with ductal carcinoma in situ from 2001 to 2018. Breast Cancer Res Treat. 2024 Dec; 208(3):577-587.
-
Development of cardiometabolic risk factors following endocrine therapy in women with breast cancer. Breast Cancer Res Treat. 2023 Aug; 201(1):117-126.
-
Endocrine therapy initiation among women with stage I-III invasive, hormone receptor-positive breast cancer from 2001-2016. Breast Cancer Res Treat. 2022 May; 193(1):203-216.
-
Serum bone markers and risk of osteoporosis and fragility fractures in women who received endocrine therapy for breast cancer: a prospective study. Breast Cancer Res Treat. 2020 Feb; 180(1):187-195.
-
Medication Use for the Risk Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2019 09 03; 322(9):868-886.
-
Changes in bone mineral density in women with breast cancer receiving aromatase inhibitor therapy. Breast Cancer Res Treat. 2018 Apr; 168(2):523-530.
-
Patterns and reasons for switching classes of hormonal therapy among women with early-stage breast cancer. Cancer Causes Control. 2017 Jun; 28(6):557-562.
-
Cardiovascular Disease After Aromatase Inhibitor Use. JAMA Oncol. 2016 Dec 01; 2(12):1590-1597.
-
Association of Adjuvant Tamoxifen and Aromatase Inhibitor Therapy With Contralateral Breast Cancer Risk Among US Women With Breast Cancer in a General Community Setting. JAMA Oncol. 2017 02 09; 3(2):186-193.
-
Psychosocial factors related to non-persistence with adjuvant endocrine therapy among women with breast cancer: the Breast Cancer Quality of Care Study (BQUAL). Breast Cancer Res Treat. 2016 05; 157(1):133-43.